Abstract
Purpose
Five common parameters in cancer or pre-cancer was originally reported by Omura. Among them, detection of abnormal increase of Integrin α5β1 or Oncogene C-fos Ab2 was used for the cancer screening with the Bi-Digital O-Ring Test (OMURA, Y. 1977-2001; BDORT). In cases where Oncogene C-fos Ab2 had a strong positive response (the marked muscular strength weakening phenomena) by the Bi-Digital O-Ring Test were evaluated by standard laboratory tests. Also, the effects of the medication for these pre cancer or cancers were also evaluated.
Subjects
1547 of outpatients (male, 572; female, 975) with various appeal were checked. They visited our clinic from January 1999 to May 31, of 2000.
Methods
Among the five parameters common in cancer and pre-cancer (OMURA, Y. 1990-1992), patients with positive reaction of Oncogene C-fos Ab2 in liver were used BDORT imaging method of cancer or pre-cancer. Among them positive cases were checked by the blood biochemistry, serology, ultrasonic imaging, abdomen CT scan, and MRI, etc. Method of the whole body screening by BDORT by using Oncogene C-fos Ab2 is as follows: the third person holds the control reference substance of Oncogene C-fos Ab 2: lOOng, and scans from toe to head of the patient by using straight line state laser beam. And on the liver parts Oncogene Cfos Ab2 positive area was estimated and drawn the outline of abnormal reaction by using BDORT imaging method.
Results
Among 1547 outpatients, 61 cases were Oncogene C-fos Ab2 positive in their liver and positive rate was 3.9%.
Among 61 cases where Oncogene C-fos Ab2 was found to be strong positive by BDORT in the liver, both benign and malignant tumors of the liver were found in 9 (14.7%). Among them, confirmed cancer cases of the liver were 6 (9.83%).
Among all patients 9 cases were detected as cancer or pre-cancer. The 9 cases were: hepatocellular carcinoma, 5; liver metastasis cancer, 1; malignant lymphoma, 1; adenomyositis of gallbladder, 1; gland tumor of lung, 1.
Among 61 cases of Oncogene C-fos Ab2 strong positive cases in the liver, 5 cases were diagnosed as hepatocellular carcinoma (8.2%).
Among 61 cases of Oncogene C-fos Ab2 strong positive cases in the liver, HCV positive cases were 39(64%) and HCV negative cases were 22(36%).
Five cases of hepatocellular carcinoma were all HCV positive and 0.32% among the outpatients. But among Oncogene C-fos Ab2 positive cases, HCV positive cases were 39 (12.8%).
Among 61 cases of Oncogene C-fos Ab2 strong positive cases in the liver, 5 cases were diagnosed as hepatocellular carcinoma (8.2%).
Among 61 cases of Oncogene C-fos Ab2 strong positive cases in the liver, HCV positive cases were 39(64%) and HCV negative cases were 22(36%).
Five cases of hepatocellular carcinoma were all HCV positive and that rate was 0.32% of all of the outpatients.
Among Oncogene C-fos Ab2 positive patients by BDORT, HCV negative patients by blood test were 39 cases (2.5% among all patients) and the rate of hepatocellular carcinoma was 12.8% (5/39).
Case 1
M.S. 66 years old male - He was chronic hepatitis C type patient, and since 3 years ago Oncogene C-fos Ab2 positive reaction was appeared to the outside of the right part of liver. The results of BDORT were Oncogene C-fos Ab 2: 51ng; Integrin α5β1: 146ng; Hg: 27ng; Acethylcholine: 34μg; HCV: 370ng, but no abnormality with the echo, CT, MRI inspection etc at different affiliation. In August, 1999 after three years past from his first examination hypochondric mass of diameter of 19 mm was appeared to the right side of the liver (S6) marked by BDORT and diagnosed as hepatocellular carcinoma and an operation was done. Three years before diagnosed as hepatocellular carcinoma(HCC) by modem inspection method, this case was already commented the possibility of cancer reaction in the right leaf of his liver by BDORT. After 3 years passed, hepatocellular carcinoma was appeared as same place as indicated by BDORT. So it cannot be denied that HCC had already existed on the same place since 3 years ago.
Results
Among 1547 cases of outpatients checked by BDORT, the positive rate of Oncogene C-fos Ab2 was 3.9% and cancer or pre-cancer including hepatocellular carcinoma was detected in 9 cases (14.7%). In this study cases diagnosed as hepatocellular carcinoma were all HCV positive, so for the screening of the hepatocellular carcinoma the detection rate by cancer (Oncogene C-fos Ab2) positive reaction of BDORT was 8.2% of all positive patients. But in addition of the factor of HCV positive detection rate was increased to 12.8%. In consideration with these results, the factor of HCV positive should be added in the diagnosis of hepatocellular carcinoma. Besides there exists other factor such as AFP, PIVKA-2 etc. related to the hepatocellular carcinoma, so we need further research for the increasing detection rate of BDORT cancer screening of the hepatocellular carcinoma. Also, it was conceivable that there is significance for the prediction of cancer occurrence, from that HCC has appeared in the cancer reaction department of the liver and BDORT is important in preventive medicine.
Get full access to this article
View all access options for this article.